cancer weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of cancer weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
European pharmaceutical company gets E.U. approval for bone marrow disorder drug
December 14th, 2004
Shire Pharmaceuticals Group plc (SHPGY) has received approval for Xagrid (anagrelide hydrochloride) for second line, monotherapy treatment of essential thrombocythemia (ET) in the European Union (E.U.), Iceland and Norway. Shire will commence a phased launch throughout Europe and expects the drug to be available for prescribing after the New Year. Xagrid, as anagrelide hydrochloride, was designated as an orphan medicinal product on December 29, 2000, for the treatment of ET, thereby providing the product with up to 10 years market exclusivity in Europe from the date of grant of the license. Essential thrombocythemia is a chronic...
Source: cancer weekly (2004-12-14)
|
